Literature DB >> 9153412

Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present.

F Chen1, P Foran, C C Shone, K A Foster, J Melling, J O Dolly.   

Abstract

Types A, B, and C1 botulinum neurotoxin (BoNT), a group of selective Zn2+-dependent endoproteases, have been instrumental in demonstrating that their respective substrates [synaptosomal-associated protein with Mr = 25 kDa (SNAP-25), synaptobrevin (Sbr), and syntaxin] are essential for regulated exocytosis from nerve terminals and neuroendocrine cells. The colocalization of Sbr, or its homologue cellubrevin (Cbr), in the majority of the glucose transporter-isotype 4 (GLUT4)-containing vesicles from adipocytes implicates their involvement in insulin-stimulated glucose uptake, which results in part from enhanced fusion of these vesicles with the plasmalemma. In this study, exposure of cultured 3T3-L1 adipocytes to BoNT/B in a low-ionic strength medium was found to block insulin-evoked glucose uptake by up to 64%. BoNT/B was shown by immunoblotting to cause extensive proteolysis of Cbr and Sbr resulting in a significant blockade of the insulin-stimulated translocation of GLUT4 to the plasmalemma. This establishes that these two toxin substrates contribute to the insulin-regulated fusion of GLUT4-containing vesicles with the plasmalemma, at least in this differentiated 3T3-L1 clone. Although SNAP-25 was not detectable in the differentiated adipocytes, its functional homologue SNAP-23 is abundant and largely confined to the plasmalemma. SNAP-23 proved to be resistant to cleavage by BoNT/A. Consistent with these results, type A did not block insulin-induced glucose uptake, precluding a demonstration of its likely importance in this process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153412     DOI: 10.1021/bi962331n

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

Review 1.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 2.  The GLUT4 code.

Authors:  Mark Larance; Georg Ramm; David E James
Journal:  Mol Endocrinol       Date:  2007-08-23

3.  Botulinum toxins inhibit the antidiuretic hormone (ADH)-stimulated increase in rabbit cortical collecting-tubule water Permeability.

Authors:  R Quigley; P Y Chu; C L Huang
Journal:  J Membr Biol       Date:  2005-04       Impact factor: 1.843

4.  VAMP2, but not VAMP3/cellubrevin, mediates insulin-dependent incorporation of GLUT4 into the plasma membrane of L6 myoblasts.

Authors:  V K Randhawa; P J Bilan; Z A Khayat; N Daneman; Z Liu; T Ramlal; A Volchuk; X R Peng; T Coppola; R Regazzi; W S Trimble; A Klip
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

5.  Role for the microtubule cytoskeleton in GLUT4 vesicle trafficking and in the regulation of insulin-stimulated glucose uptake.

Authors:  L M Fletcher; G I Welsh; P B Oatey; J M Tavaré
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

6.  Plasma membrane localization signals in the light chain of botulinum neurotoxin.

Authors:  Ester Fernández-Salas; Lance E Steward; Helen Ho; Patton E Garay; Sarah W Sun; Marcella A Gilmore; Joseph V Ordas; Joanne Wang; Joseph Francis; K Roger Aoki
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 7.  Targeted secretion inhibitors-innovative protein therapeutics.

Authors:  Foster Keith; Chaddock John
Journal:  Toxins (Basel)       Date:  2010-12-03       Impact factor: 4.546

Review 8.  Towards new uses of botulinum toxin as a novel therapeutic tool.

Authors:  Andy Pickett; Karen Perrow
Journal:  Toxins (Basel)       Date:  2011-01-12       Impact factor: 4.546

9.  Engineering an Effective Human SNAP-23 Cleaving Botulinum Neurotoxin A Variant.

Authors:  Stefan Sikorra; Sarah Donald; Mark Elliott; Susan Schwede; Shu-Fen Coker; Adam P Kupinski; Vineeta Tripathi; Keith Foster; Matthew Beard; Thomas Binz
Journal:  Toxins (Basel)       Date:  2020-12-18       Impact factor: 4.546

10.  Nonparalytic botulinum molecules for the control of pain.

Authors:  Antonina S Mangione; Ilona Obara; Maria Maiarú; Sandrine M Geranton; Cristina Tassorelli; Enrico Ferrari; Charlotte Leese; Bazbek Davletov; Stephen P Hunt
Journal:  Pain       Date:  2016-05       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.